Emergent BioSolutions wins $22.3m BioThrax order as US military maintains anthrax preparedness
Emergent BioSolutions has secured a modification worth up to $22.3 million under an existing US military supply arrangement for BioThrax. Initial deliveries worth approximately $7.4 million are expected in 2026, with the balance scheduled for 2027, supporting biodefence procurement as the company's wider financial recovery remains under pressure.